Dear Editor,

Limb-girdle muscular dystrophies type 1D (LGMD1D) is generally known as an adult-onset musculoskeletal disease. However, according to reports, there are cases of onset in children, including Nam, et al.\'s study.[@B1] Although most patients with LGMD1D are characterized by an onset in adulthood, some develop at an early age, and as noted, the age of disease onset can vary. Our patients also presented with various clinical manifestations. In our patients, there was no significant evidence of cardiac involvement based on past history, clinical symptoms and signs, findings on physical examination, laboratory data, and chest X-ray. The possibility of subclinical cardiac abnormality in our patients cannot be ruled out completely, however, alhough we believe that our patients did not have cardiac abnormalities at that time.

In addition, serum creatine kinase (CK) levels (our normal range: 35--232 IU/L) are a useful clinical biomarker, but fluctuate and vary, even at low levels in a muscle atrophy state. The serum CK levels of our patients were normal to mildly elevated. The first patient had a CK level of 175 IU/L, and the second patient had levels of 504 IU/L and 673 IU/L on two tests. The last patient had a level of 301 IU/L.

We also agree that the phenotype of LGMD1D may appear more heterogeneous than we thought. This has been confirmed from the paper published by Ruggieri, et al.[@B2] According to the paper, patients with proximal G/F domain mutations (Phe89, Phe91, and Phe93) in *DNAJB6* show proximal limbgirdle weakness, whereas patients with distal G/F domain mutations (Pro96 and Phe100) expereience distal leg weakness.

We stated more than nine mutations in the *DNAJB6* gene have been reported, including p.Phe89Ile, p.Phe91Ile, pPhe-91Leu, p.Phe93Ile, p.Phe93Leu, p.Pro96Arg, p.Pro96Leu, p.Phe-100Val, and p.Phe100Ile. Recently, two mutations (c.284A\>T, p.Asn95Ile, two families; and c.293_295delATG, p.Asp98del, one family) were reported.[@B3] Thus, at least 11 different mutations have been identified so far ([Table 1](#T1){ref-type="table"}). As next generation sequencing becomes more wildly used, additional novel mutations will be identified.
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###### Clinical Features and Genetic Findings for *DNAJB6* Mutations
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  Genotype                  References              Region of study    Onset age             Distribution of weakness   Serum CK                                           Muscle pathology                                   Bulbar symptoms
  ------------------------- ----------------------- ------------------ --------------------- -------------------------- -------------------------------------------------- -------------------------------------------------- -----------------
  p.Phe89Ile                Kim, et al.[@B4]        Asia               30--40                Proximal                   NL                                                 N/A                                                None
  Couthouis, et al.[@B5]    America                 8--18              Proximal              NL                         RV                                                 \-                                                 
  Sarparanta, et al.[@B6]   America                 20--55             Proximal              NL--10×                    Myopathic, RV                                      Yes                                                
  p.Phe91Ile                Palmio, et al.[@B7]     Europe             6--13                 Proximal                   NL--2×                                             RV, fibrosis, atrophy, myofibrillar aggregations   None
  Ruggieri, et al.[@B2]     Europe                  16                 Proximal              NL                         Dystrophic, RV                                     None                                               
  p.Phe91Leu                Nam, et al.[@B1]        Asia               8--11                 Proximal                   NL--2×                                             RV                                                 None
  Palmio, et al.[@B7]       Europe                  15                 Proximal and distal   NL                         RV, Fibrosis, atrophy, myofibrillar aggregations   Yes                                                
  Ruggieri, et al.[@B2]     Europe                  11                 Proximal              NL                         Myopathic, RV                                      Yes                                                
  p.Phe93Ile                Sato, et al.[@B8]       Asia               30s                   Proximal                   1.5--5×                                            Myopathic, RV                                      None
  p.Phe93Leu                Harm, et al.[@B9]       America            30--40                Proximal                   3--6×                                              Myopathic, RV                                      None
  Ruggieri, et al.[@B2]     Europe                  45                 Proximal              NL                         Myopathic, RV                                      None                                               
  p.Ans95Ile                Jonson, et al.[@B3]     Europe             36--55                Distal                     NL--2×                                             RV                                                 Yes
  p.Pro96Arg                Harm, et al.[@B9]       African American   18--35                Distal                     2×                                                 N/A                                                None
  p.Pro96Leu                Tsai, et al.[@B10]      Asia               30--40                Proximal                   NL                                                 Fatty change                                       Yes
  p.Asp98del                Jonson, et al.[@B3]     Europe             16, 20                Proximal and distal        2×                                                 RV                                                 None
  p.Phe100Val               Ruggieri, et al.[@B2]   Europe             10--50                Proximal and distal        1.5--4×                                            RV                                                 Yes
  p.Phe100Ile               Kim, et al.[@B4]        Asia               17, 27                Proximal and distal        3×                                                 RV                                                 Yes

N/A, not available; NL, normal; RV, rimmed vacuole.
